Parkinson’s Disease Treatment Market
Parkinson’s Disease Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological Treatments, Device-Based Treatments, Surgical Procedures, and Non-Pharmacological Therapies), By Drug Class (Levodopa + Carbidopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, and Other Drugs), By End User (Hospitals, Neurology Clinics, Ambulatory Surgical Centers, and Home Care Settings), Forecast Period (2026–2035)
Industry Overview
Parkinson’s disease treatment Market size was valued at $12.2 billion in 2025 and is projected to reach $22.6 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2026–2035). Market growth is primarily driven by the increasing prevalence of neurological disorders and the rising geriatric population globally. According to the World Health Organization (WHO), more than 8.5 million people were living with Parkinson’s disease globally, and its prevalence has doubled over the past 25 years. Additionally, the OECD reports that aging populations are expanding rapidly, with individuals aged 65+ expected to account for nearly 27% of the population in developed economies by 2050, significantly increasing disease burden. Pharmacological treatments, such as Levodopa + Carbidopa, dominate the market, while device-based therapies, such as Deep Brain Stimulation (DBS), are gaining traction. Key end users include hospitals, neurology clinics, and ambulatory surgical centers. Continuous innovation in drug formulations and neuromodulation technologies is further strengthening the global outlook for the parkinson’s disease treatment industry.
Market Dynamics
Rising Aging Population and Increasing Neurological Disease Burden Driving Market Growth
The growth of the parkinson’s disease treatment Market is strongly influenced by the rising geriatric population and increasing neurological disease incidence. According to the WHO, Parkinson’s disease is the fastest-growing neurological disorder globally, with cases increasing by over 100% since 2000. The European Federation of Pharmaceutical Industries and Associations (EFPIA) highlights that neurological disorders account for a significant share of healthcare expenditure in Europe, underscoring the growing demand for advanced therapies. Governments and organizations are actively investing in treatment innovation. For instance, between 2025 and 2026, the U.S. Food and Drug Administration (FDA) accelerated approvals for advanced neuromodulation devices and extended-release drug formulations to improve patient outcomes. Pharmaceutical companies are focusing on combination therapies and long-acting formulations to enhance efficacy and adherence. These strategic initiatives, combined with increased awareness and early diagnosis, are significantly boosting the growth of the parkinson’s disease treatment market globally.
High Treatment Costs and Limited Curative Therapies Pose Challenges
Despite strong growth, the parkinson’s disease treatment Market faces significant challenges, including high treatment costs and a lack of curative solutions. Advanced therapies such as Deep Brain Stimulation (DBS) involve substantial procedural and device costs, limiting accessibility in developing economies. According to the OECD, healthcare cost inflation continues to rise, placing pressure on public healthcare systems and patients alike. Additionally, current treatments primarily focus on symptom management rather than disease modification. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights that neurological drug development has a high failure rate due to complex disease mechanisms, leading to increased R&D costs. Supply chain disruptions and regulatory hurdles further complicate market expansion. However, companies are responding with innovative approaches such as gene therapy, stem cell therapy, and infusion-based delivery systems. These advancements aim to overcome therapeutic limitations and improve long-term outcomes, shaping the future of the parkinson’s disease treatment industry trends.
Market Segmentation
- Based on the treatment type, the market is segmented into pharmacological treatments, device-based treatments, surgical procedures, and non-pharmacological therapies.
- Based on the technology, the market is segmented into conventional drug therapies, controlled/extended-release formulations, infusion-based therapies, neuromodulation technologies, gene therapy, and stem cell therapy.
- Based on the drug class, the market is segmented into levodopa + carbidopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and other drugs.
- Based on the end user, the market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and home care settings.
Pharmacological Treatments Segment Leads the Market
Pharmacological treatments dominate the parkinson’s disease treatment market share, driven by widespread adoption and clinical effectiveness. Levodopa + Carbidopa remains the most prescribed therapy due to its proven efficacy in managing motor symptoms. The demand for dopamine agonists and MAO-B inhibitors is also increasing as combination therapies become more common.
Between 2022 and 2026, pharmaceutical companies have focused on developing controlled-release formulations to improve drug delivery and reduce side effects. Organizations such as PhRMA report increasing R&D investments in neurological drugs, supporting innovation in treatment approaches. The accessibility, cost-effectiveness, and strong clinical validation of pharmacological treatments continue to reinforce their dominance across hospitals and neurology clinics globally.
Neuromodulation Technologies Segment to Record Strong Growth
Neuromodulation technologies, particularly Deep Brain Stimulation (DBS) systems, are expected to witness the fastest growth during the forecast period. These technologies offer significant benefits for patients with advanced Parkinson’s disease who do not respond effectively to medications. Technological advancements such as adaptive DBS and AI-integrated stimulation systems are improving precision and outcomes. According to the FDA, approvals for next-generation DBS devices have increased significantly between 2024 and 2026, reflecting growing clinical adoption. Investment in innovative therapies, coupled with rising awareness and favorable reimbursement policies in developed regions, is accelerating the segment's growth. Additionally, emerging therapies such as gene and stem cell treatments are expected further to transform the parkinson’s disease treatment market forecast.
Regional Outlook
The global parkinson’s disease treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the parkinson’s disease treatment market due to its advanced healthcare infrastructure and strong R&D investments. According to the National Institutes of Health (NIH), annual funding for Parkinson’s research exceeds $300 million, supporting innovation in drug development and neuromodulation technologies. Additionally, the FDA plays a crucial role in accelerating approvals for new therapies, enhancing market growth. The rising prevalence of Parkinson’s disease and increasing adoption of advanced treatments further strengthen the country’s leadership in the global market.
China to Record Strong Growth
China is expected to witness significant growth in the parkinson’s disease treatment market due to expanding healthcare infrastructure and increasing disease awareness. According to the WHO, the Asia-Pacific region accounts for a substantial share of the global aging population, driving demand for neurological treatments. Government initiatives to improve healthcare access and investments in pharmaceutical manufacturing are boosting market expansion. Additionally, increasing clinical trials and collaborations with global pharmaceutical companies are accelerating innovation and improving treatment availability in the region.
Market Player Outlook
The parkinson’s disease treatment market is highly competitive, characterized by strong R&D capabilities and technological innovation. Key players are focusing on expanding their product portfolios, enhancing drug formulations, and investing in neuromodulation technologies. Companies such as Medtronic plc, Lundbeck A/S, Acadia Pharmaceuticals, Mitsubishi Tanabe Pharma, and Boston Scientific are actively pursuing strategic initiatives, including product development, partnerships, and geographic expansion. Their focus on advanced therapies and personalized medicine is strengthening their competitive positioning in the global market.
Recent Development
- In March 2026, Lundbeck announced that it is initiating a Phase 2 clinical trial for Lu AF28996, an investigational oral D1/D2 receptor agonist. Recent Phase 1b data presented at the AD/PD 2026 conference showed the compound was well-tolerated and provided continuous dopaminergic stimulation. The drug is specifically designed to reduce OFF time and levodopa-induced dyskinesia in patients with advanced parkinson’s.
- In January 2025, Medtronic achieved CE Mark approval for its BrainSense Adaptive Deep Brain Stimulation (aDBS) system and Electrode Identifier. This technology represents a major leap in personalized medicine, as it is the world’s only closed-loop DBS system that can sense brain signals and automatically adjust stimulation levels in real-time to match the patient’s changing needs. This follows the US FDA's approval of the same adaptive technology in early 2024.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global parkinson’s disease treatment market. Based on data availability, the report also includes information on new products and relevant news.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Parkinson’s Disease Treatment Market Sales Analysis – Treatment Type | End User | Drug Class | Country ($ Million)
- Parkinson’s Disease Treatment Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Parkinson’s Disease Treatment Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Parkinson’s Disease Treatment Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers for the Global Parkinson’s Disease Treatment Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Parkinson’s Disease Treatment Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities for the Global Parkinson’s Disease Treatment Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Parkinson’s Disease Treatment Market Revenue and Share by Manufacturers
- Parkinson’s Disease Treatment Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 Medtronic plc
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Lundbeck A/S
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Acadia Pharmaceuticals
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Mitsubishi Tanabe Pharma
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Boston Scientific
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Parkinson’s Disease Treatment Market Sales Analysis by Treatment Type ($ Million)
5.1 Pharmacological Treatments
5.2 Device-Based Treatments
5.3 Surgical Procedures
5.4 Non-Pharmacological Therapies
- Global Parkinson’s Disease Treatment Market Sales Analysis by End User ($ Million)
7.1 Hospitals
7.2 Neurology Clinics
7.3 Ambulatory Surgical Centers (ASCs)
7.4 Home Care Settings
- Global Parkinson’s Disease Treatment Market Sales Analysis by Drug Class ($ Million)
8.1 Levodopa + Carbidopa
8.2 Dopamine Agonists
8.3 MAO-B Inhibitors
8.4 COMT Inhibitors
8.5 Other Drugs (Anticholinergics & Amantadine)
- Regional Analysis
9.1 North American Parkinson’s Disease Treatment Market Sales Analysis – Treatment Type | End User | Drug Class | Country ($ Million)
9.1.1 United States
9.1.2 Canada
9.2 European Parkinson’s Disease Treatment Market Sales Analysis – Treatment Type | End User | Drug Class | Country ($ Million)
9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Asia-Pacific Parkinson’s Disease Treatment Market Sales Analysis – Treatment Type | End User | Drug Class | Country ($ Million)
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific
9.4 Rest of the World Parkinson’s Disease Treatment Market Sales Analysis – Treatment Type | End User | Drug Class | Country ($ Million)
9.4.1 Latin America
9.4.2 Middle East and Africa
- Company Profiles
10.1 Abbott Laboratories
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.2 AbbVie Inc.
10.2.1 Quick Facts
10.2.2 Company Overview
10.2 Product Portfolio
10.2.4 Business Strategies
10.3 Amneal Pharmaceuticals, Inc.
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.4 Bayer AG (BlueRock Therapeutics)
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.5 Bial - Portela & Ca, S.A.
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.6 Biogen Inc.
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.7 Britannia Pharmaceuticals (STADA Group)
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.8 F. Hoffmann-La Roche Ltd
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.9 GlaxoSmithKline plc (GSK)
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.10 Hikma Pharmaceuticals PLC
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.11 Kyowa Kirin Co., Ltd.
10.11.1 Quick Facts
10.11.2 Company Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.12 Neurocrine Biosciences, Inc.
12.12.1 Quick Facts
10.12.2 Company Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.13 Novartis AG
10.13.1 Quick Facts
10.13.2 Company Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.14 Sun Pharmaceutical Industries Ltd.
10.14.1 Quick Facts
10.14.2 Company Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.15 Sunovion Pharmaceuticals (Sumitomo Pharma)
10.15.1 Quick Facts
10.15.2 Company Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.16 Supernus Pharmaceuticals, Inc.
10.16.1 Quick Facts
10.16.2 Company Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.17 Teva Pharmaceutical Industries Ltd.
10.17.1 Quick Facts
10.17.2 Company Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.18 UCB S.A.
10.18.1 Quick Facts
10.18.2 Company Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.19 Zambon S.p.A.
10.19.1 Quick Facts
10.19.2 Company Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies
1. Global Parkinson’s Disease Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
2. Global Pharmacological Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Device-Based Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Surgical Procedures Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Non-Pharmacological Therapies Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Parkinson’s Disease Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
7. Global Hospitals Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Neurology Clinics Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Ambulatory Surgical Centers Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Home Care Settings Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Parkinson’s Disease Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
12. Global Levodopa + Carbidopa Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Dopamine Agonists Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global MAO-B Inhibitors Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global COMT Inhibitors Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Other Drugs Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Parkinson’s Disease Treatment Market by Region, 2025–2035 ($ Million)
18. North America Parkinson’s Disease Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
19. North America Parkinson’s Disease Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
20. North America Parkinson’s Disease Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
21. North America Parkinson’s Disease Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
22. Europe Parkinson’s Disease Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
23. Europe Parkinson’s Disease Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
24. Europe Parkinson’s Disease Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
25. Europe Parkinson’s Disease Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
26. Asia-Pacific Parkinson’s Disease Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
27. Asia-Pacific Parkinson’s Disease Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
28. Asia-Pacific Parkinson’s Disease Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
24 Asia-Pacific Parkinson’s Disease Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
29. Rest of the World Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
30. Rest of the World Parkinson’s Disease Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
31. Rest of the World Parkinson’s Disease Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
32. Rest of the World Parkinson’s Disease Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
1. Global Parkinson’s Disease Treatment Market Share by Segment, 2025 Vs 2035 (%)
2. Global Pharmacological Parkinson’s Disease Treatment Market Share by Region, 2025 vs 2035 (%)
3. Global Device-Based Parkinson’s Disease Treatment Market Share by Region, 2025 vs 2035 (%)
4. Global Surgical Procedures Parkinson’s Disease Treatment Market Share by Region, 2025 Vs 2035 (%)
5. Global Non-Pharmacological Therapies Parkinson’s Disease Treatment Market Share by Region, 2025 Vs 2035 (%)
6. Global Levodopa + Carbidopa Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Dopamine Agonists Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global MAO-B Inhibitors Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global COMT Inhibitors Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Other Drugs Parkinson’s Disease Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Parkinson’s Disease Treatment Market Share by Region, 2025 vs Parkinson's 2035 (%)
12. United States Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
13. Canada Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
14. UK Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
15. France Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
16. Germany Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
17. Italy Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
18. Spain Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
19. Russia Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
20. India Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
21. China Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
22. Japan Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
23. South Korea Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
24. Australia & New Zealand Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
25. ASEAN Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
26. Rest of Asia-Pacific Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
27. Latin America Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
28. Middle East & Africa Parkinson’s Disease Treatment Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
